Xeris Pharmaceuticals (XERS) revenue breakdown
By product, Product revenue, net is the largest at 97% of fiscal 2025 revenue, growing 36% a year over 2 years.
Revenue by product
Fiscal years, as Xeris Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $292M.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Product revenue, net | — | — | $153M | $197M | $283M | 97% |
| Royalty, contract and other revenue | $310,000 | $985,000 | $11M | $6M | $9M | 3% |
| Gvoke | $39M | $53M | — | — | — | — |
| Keveyis | $10M | $49M | — | — | — | — |
| Recorlev | — | $7M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for XERS.
Open XERS in InvestinglyQuestions
Where does Xeris Pharmaceuticals make its money?
In fiscal 2025, by product: Product revenue, net $283M, Royalty, contract and other revenue $9M.
From Xeris Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.